financetom
Business
financetom
/
Business
/
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Jan 21, 2025 8:47 AM

Shares of Eli Lilly ( LLY ) and Company are trading higher after getting pummeled on Friday. The move lower happened after the company announced preliminary sales that were less than expected. The sales were $45 billion and investors were looking for $46 billion.

There's a good chance that the move lower is over. There is also a good chance that the stock is about to rebound. This is why our team of technical analysts and traders has made it our Stock of the Day.

As you can see on the chart, there has been support around $722.

If a stock is trending lower, there is more supply (sell orders) than there is demand (buy orders). Those who wish to sell are forced to offer their shares at a discount to draw buyers into the market. This pushes the stock into a downtrend.

At a support level, the dynamic changes. There is enough demand to absorb all of the supply. This puts a floor under the price.

Read Also: Apple’s AI Advances Can’t Offset Chinese Market Slowdown, Says Analyst

Support levels can stay intact for an extended period of time because of remorseful sellers.

There are traders and investors who sold shares for around $722 in March who regretted doing so when the stock rallied soon after. Some of them decided that if they could, they would buy their shares back at the same price they were sold for.

So, when the stock returned to around the $722 level in April they placed buy orders. The large number of these buy orders caused support to form at the same price that had been support before.

Similar price action occurred in November.

Regretful traders and investors who sold around $722 in April placed buy orders to get their shares back at their selling prices. The large number of these orders created support at the level again.

As you can see, each time Lilly found this support a move higher followed. On Friday, the stock found support at the level once again. The stage may be set for another rebound.

Read Next:

Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Baidu Completes $617.6 Million Senior Notes Offering
Baidu Completes $617.6 Million Senior Notes Offering
Sep 15, 2025
08:07 AM EDT, 09/15/2025 (MT Newswires) -- Baidu ( BIDU ) said Monday it completed a senor notes offering of 4.4 billion Chinese renminbi ($617.6 million). The offering consisted of 1.9% senior unsecured notes due 2029 sold via offshore transactions to certain non-US persons, the company said. Net proceeds will be used for general corporate purposes, including repayment of existing...
Artemis Gold to Spend Up to $110 Million to Boost Blackwater Mine Phase-One Capacity by 33%
Artemis Gold to Spend Up to $110 Million to Boost Blackwater Mine Phase-One Capacity by 33%
Sep 15, 2025
08:06 AM EDT, 09/15/2025 (MT Newswires) -- Artemis Gold ( ARGTF ) said Monday it will invest $100 million to $110 million to expand phase-one processing capacity at its Blackwater mine in British Columbia. The upgrade will increase the phase-one processing plant's nameplate capacity by 33% to 8 million tonnes per year from 6 million tonnes, the company said. We...
MEG Energy urges investors to reject Strathcona's sweetened bid, backs Cenovus deal
MEG Energy urges investors to reject Strathcona's sweetened bid, backs Cenovus deal
Sep 15, 2025
Sept 15 (Reuters) - Canadian oil sands producer MEG Energy ( MEGEF ) on Monday urged shareholders to reject the sweetened takeover bid from its majority stakeholder Strathcona Resources ( STHRF ), and reaffirmed support for sale to Cenovus Energy ( CVE ). The revised Strathcona offer remains fundamentally unattractive, said James McFarland, chair of MEG's board, citing exposure to...
aTyr Pharma's Phase 3 Trial of Lung Disease Treatment Misses Primary Endpoint
aTyr Pharma's Phase 3 Trial of Lung Disease Treatment Misses Primary Endpoint
Sep 15, 2025
08:05 AM EDT, 09/15/2025 (MT Newswires) -- aTyr Pharma ( ATYR ) reported Monday that a phase 3 study of efzofitimod to treat pulmonary sarcoidosis, a type of lung disease, missed its primary endpoint. The study's primary endpoint was the change from baseline in mean daily oral corticosteroid dose at week 48. The biotech company said it will seek a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved